2021 National Comprehensive Cancer Network(NCCN), All rights reserved. NCCN Guidelinesand this illustration may not be reproduced in any form without the express written permission of NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines?) Prostate Cancer Version 2.2021 — February 17, ...
Prostate Cancer: Community Education and Disparities inDiagnosis and TreatmentB RADLEY C ARTHON , H ANNAH C. S IBOLD , S HANNON B LEE , R EBECCA D. P ENTZWinship Cancer Institute, Emory University, Atlanta, Georgia, USADisclosures of potential conf l icts of interest may be found at the...
The treatment of advanced prostate cancer has evolved due to recent advances in molecular research and new drug development. Dynamic aberrations in the androgen receptor, DNA repair genes, PTEN-PI3K, and other pathways drive the behavior of advanced prostate cancer allowing a better selection of ...
"Watch and wait," is a phrase that is being used more frequently to describe a program of active surveillance without other cancer treatment for some patients with prostate cancer. It means that if your cancer is not aggressive (based on the Gleason score and the cancer stage), treatments ma...
Genetic testing, to identify pathogenic or likely pathogenic variants in prostate cancer, is valuable in guiding treatment decisions for men with prostate cancer and to inform cancer prevention and early detection options for their immediate blood relatives. There are various guidelines and consensus stat...
Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors Article Open access 08 February 2021 Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-...
Prostate cancer screening guidelines have been controversial (Wilt 2015; Etzioni 2014; Payton 2012; Tabayoyong 2015). As increasing numbers of men were being screened, critics became concerned that too many men were undergoing invasive diagnostic procedures only to find out they did not have cancer...
Androgen deprivation therapy (ADT) remains the standard treatment for metastatic prostate cancer. ADT intensification is now a standard of care in the management of metastatic prostate cancer. This intensification is discussed in relation to the patient and the characteristics of the disease. For all ...
Androgen deprivation therapy (ADT) has been a mainstay of treatment for advanced prostate cancer (PCa), but limited studies have been performed to investigate the association between ADT and autoimmune diseases. We conducted a population-based nationwide
Article Open access 06 September 2021 Integrated aerobic exercise with LDE-docetaxel treatment: a novel approach to combat prostate cancer progression Article Open access 26 April 2024 Introduction Radiotherapy is a cornerstone in the management of cancer and used to treat a myriad of malignancies,...